Pentair (PNR)
(Delayed Data from NYSE)
$87.88 USD
+0.59 (0.68%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $87.89 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.88 USD
+0.59 (0.68%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $87.89 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Pentair (PNR) Q3 Earnings, Revenue Top Estimates
by Madhurima Das
Pentair (PNR) Q3 earnings and revenues beat the respective Zacks Consensus Estimate.
Why Pentair (PNR) Might Surprise This Earnings Season
by Zacks Equity Research
Pentair (PNR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Grainger (GWW) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Grainger's (GWW) third-quarter results are likely to reflect coronavirus-induced demand for certain products and e-commerce sales, offset by lower demand in manufacturing and transportation industries.
Avery Dennison (AVY) to Report Q3 Earnings: What to Expect?
by Zacks Equity Research
Avery Dennison's (AVY) Q3 results likely to reflect high demand in the Label and Packaging Materials business. However, impact of COVID-19 on apparel and industrial-end markets will offset these gains.
Pentair (PNR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Pentair (PNR) third-quarter results are likely to reflect benefits from cost-cutting efforts and improvement in its residential facing business, offset by weakness in commercial business due to the pandemic.
Here's Why Hold Strategy is Apt for Pentair (PNR) Stock Now
by Zacks Equity Research
Positive estimate revisions, cost savings and product innovation are some of the factors that make Pentair (PNR) stock worth retaining in the portfolio.
Lakeland (LAKE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Lakeland Industries' (LAKE) fiscal second-quarter results are expected to reflect solid demand for personal protective equipments related to the pandemic. Also, solid manufacturing capabilities and customer base are likely to have been tailwinds.
Zebra Acquires Reflexis Systems, Boosts Software Offerings
by Zacks Equity Research
Zebra's (ZBRA) Reflexis Systems purchase is likely to solidify its existing software offerings in multiple end markets. Earnings accretion is anticipated after the first year of the buyout completion.
Pentair (PNR) Beats on Q2 Earnings & Sales, Initiates Guidance
by Zacks Equity Research
Pentair (PNR) delivers better-than-expected Q2 performance and projects adjusted earnings per share (EPS) between $2.00 and $2.20 for the current year.
Pentair (PNR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Pentair (PNR) Q2 results to reflect benefits from cost-cutting efforts, investments in water-treatment solutions and productivity improvement amid suspension of operations on the coronavirus crisis.
Pentair Rides on Investments & Acquisitions Amid Weak Demand
by Zacks Equity Research
Pentair (PNR) likely to benefit from investments in water treatment solutions, productivity improvement and cost-control initiatives amid weak demand due to the coronavirus crisis.
Weak Demand & Lower Production to Impact Pentair (PNR)
by Zacks Equity Research
Pentair's (PNR) near-term results might be hurt by production curtailment and weak demand across its business amid the coronavirus crisis.
Pentair (PNR) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Pentair (PNR) delivers a better-than-expected Q1 performance and withdraws guidance for 2020 due to the uncertainty of the duration and extent of the COVID-19 pandemic impact.
Industrial Stock Earnings Due on Apr 30: PH, SWK & More
by Avisekh Bhattacharjee
The impacts of the coronavirus outbreak, cost-related woes, and other headwinds are expected to get reflected in the results of the majority of industrial stocks in Q1.
Pentair (PNR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Pentair's (PNR) Q1 results are likely to reflect benefits from investments in water-treatment solutions and productivity improvement amid suspensions of operations on the coronavirus outbreak.
Pentair Halts Operations, Pulls Guidance on Coronavirus Scare
by Zacks Equity Research
Pentair (PNR) suspends operations in major facilities and withdraws financial outlook.
Pentair (PNR) Q4 Earnings & Revenue Top Estimates
by Madhurima Das
Pentair's (PNR) Q4 earnings and revenues surpassed the respective Zacks Consensus Estimate.
Pentair (PNR) Q4 Earnings & Revenue Top Estimates
by Madhurima Das
Pentair's (PNR) Q4 earnings and revenues surpassed the respective Zacks Consensus Estimate.
Pentair (PNR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Pentair's (PNR) Q4 performance likely to reflect benefits from productivity improvement and price hikes amid higher input costs.
5 Industrial Stocks Set for a Beat This Earnings Season
by Madhurima Das
Despite a weak manufacturing sector weighing down on the Industrial Products Sector, these five stocks are poised to beat estimates in the upcoming reporting cycle.
Pentair Shuts Down Aquaculture Business, Divests Vaki Unit
by Zacks Equity Research
Pentair (PNR) divests Vaki business unit to focus on the residential and commercial pool segments.
FDA Panel Laps Up Merck's Keytruda & Lynparza for New Maladies
by Zacks Equity Research
The FDA's ODAC votes in favor of Merck's (MRK) Keytruda for non-muscle invasive bladder cancer. The panel also backs Lynparza as a first-line maintenance monotherapy for pancreatic cancer.
Factors Setting the Tone for Apogee's (APOG) Q3 Earnings
by Zacks Equity Research
Apogee's (APOG) Q3 performance likely to reflect benefits from solid bidding and order activities, robust backlog, and an upbeat North America commercial construction market.
Pentair (PNR) Beats on Q3 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Pentair's (PNR) Q3 earnings beat the Zacks Consensus Estimate and reaffirmed its adjusted EPS guidance at $2.35 for 2019.
Pentair (PNR) Beats Q3 Earnings, Lags Revenue Estimates
by Zacks Equity Research
Pentair's (PNR) Q3 adjusted earnings of 58 cents beat the Zacks Consensus Estimate of 55 cents.